The global eye allergy treatment market is mainly driven by the growing awareness about eye disorders and the growing demand from consumers for effective eye allergy medications. The eyes are among the most delicate organs in the human body and can be grossly affected by several factors, including imbalances in the body as well as extreme changes in the environment. This has driven significant research and development activity in the global eye allergy treatment market in recent years, as ophthalmology has advanced significantly as a major area of medicine. The growing geriatric population is also likely to be a key driver for the global eye allergy treatment market over the forecast period. The eyes grow weak with age, leading to a higher prevalence of ophthalmological conditions among the geriatric than among younger demographics.             

The global eye allergy treatment market is expected to exhibit a strong 5.3% CAGR over the forecast period from 2018 to 2023, according to the latest research report from Market Research Future (MRFR). The report presents a detailed analysis of the global eye allergy treatment market, profiling the leading drivers and restraints operating on the market. The major economic factors operating in the market’s environment are also studied in the report to understand the market’s economic position and standing. The major players operating in the global eye allergy treatment market are also profiled in the report to provide readers with a clear picture of the market’s competitive landscape.

Growing air pollution is also likely to be a major driver for the global eye allergy treatment market over the forecast period. Air pollution is a major causative agent for eye allergies, as dust, pollen and other particles are borne on air pollution and can easily reach the eyes. Growing urbanization around the world has driven the extent of air pollution, leading to a growing prevalence of eye allergies. This is likely to drive the demand from the eye allergy treatment market over the forecast period.

Competitive Analysis:

Leading players in the global eye allergy treatment market include Nutra Essential OTC, Shire, Akorn Inc., Nicox, Teva Pharmaceutical Industries Ltd., Santen Pharmaceutical Co. Ltd., Bausch Health, Novartis AG, Johnson Johnson Services Inc., and Allergan plc. Research into developing more effective formulations for eye allergy treatment is likely to remain a popular avenue among players in the global eye allergy treatment market over the forecast period. Developing formulations with safer ingredients that don’t affect the eyes adversely is also likely to be a priority for players in the eye allergy treatment market.

Segmentation:

The global eye allergy treatment market is segmented on the basis of type, treatment, end use, and region.

By type, the global eye allergy treatment market is segmented into seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, contact allergy conjunctivitis, and giant papillary conjunctivitis.

By treatment, the global eye allergy treatment market is segmented into medications and allergy shots (immunotherapy). The medications segment is further segmented into artificial tears, decongestants, antihistamines/mast cell stabilizers, oral antihistamines, and corticosteroids. The allergy shots segment is further sub-segmented into subcutaneous immunotherapy treatment and sublingual immunotherapy treatment.

By end use, the global eye allergy treatment market is segmented into hospitals and clinics, and specialty centers.

Regional Analysis:

The Americas hold the largest share of more than 40% in the global eye allergy treatment market and is likely to remain the leading regional market over the forecast period. The Americas market for eye allergy treatment is mainly driven by the growing prevalence of ophthalmological conditions in North America, the growing awareness about ophthalmological conditions, and the growing geriatric population in the region. According to the National Eye Institute, about 3 million cases of conjunctivitis were reported in the U.S. in 2015.